CGT Catapult to Collaborate with Oxford MEStar and AK (Suzhou) Biomedical as Part of Jiangsu-UK Industrial Challenge Programme
Date: January 16, 2018
Cell and Gene Therapy Catapult announce collaboration with Oxford MEStar and AK (Suzhou) Biomedical
The collaboration, funded by the Jiangsu-UK Industrial Challenge Programme, will develop a novel manufacturing process for CAR-T cell cancer therapy. These are innovative but expensive treatments which can cost around $500,000 per treatment.
The project expects to be able to reduce production costs greatly.
Oxford MEStar is a bioengineering company based in Oxford which specialises in bioreactor systems and automated cell processing production and scale-up. Together with AK (Suzhou) Biomedical, a Chinese biotech specialising in products and services for clinical applications and the Catapult, this team will focus on introducing greater automation and closed system processing into the production system.
Back to News Overview